Applying Appropriate Use Criteria for Cardiac Imaging: Improving CHD Screening and Diagnosis

Applying Appropriate Use Criteria for Cardiac Imaging: Improving CHD Screening and Diagnosis

On-Demand Webcast

This webcast is based on live proceedings from a symposium conducted at the 2019 Cardiometabolic Risk Summit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.


David Wolinsky, MD, FACC, MASNC
Past President
American Society Nuclear Cardiology
Section Head Nuclear Cardiology
Cleveland Clinic Florida 
Weston, Florida

Intended Learners

This activity is designed for primary care physicians, family medicine specialists, internists, pediatricians, nurse practitioners, nurses, physician assistants, pharmacists, registered dietitians, certified diabetes educators, and other related healthcare professionals involved in the treatment of patients at risk for cardiometabolic syndrome. 

Learning Objectives

After completing this activity, participants should be able to:

  • Describe the established risk factors for CHD and the role of cardiac imaging in risk modification and prevention strategies
  • Highlight recent advances with respect to the sensitivity, accessibility, and invasiveness of available cardiac imaging techniques
  • Evaluate the safety and indications of available agents for pharmacologic stress testing and the patient populations in which this procedure should be employed
  • Apply appropriate use criteria to facilitate selection of the optimal cardiac imaging modality for the early detection of CHD in a given patien
Activity Overview

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10 question post-test with a score of 70% or better, and complete the evaluation form.

After successful completion of the post-test and evaluation form online at, participants may immediately print their documentation of credit.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Release Date: December 10, 2019
Expiration Date: December 10, 2020
Estimated time to complete: 45 minutes

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

There is no fee associated with this activity.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to


    In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



NACCME designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 0.75 contact hours.


This enduring activity is approved for .75 contact hour (.075 CEUs) of continuing pharmacy education (JA0006201-0000-20-031-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises David Wolinsky, MD, FACC, MASNC, Susie Seaman, NP; Jennifer Browne, Molly, Duda, Mary Johnson, Jennifer Ilcyn, Mike Kearney, Todd Kunkler, and Chris Bolwell, NACCME

Independent Clinical Reviewer: Peter Oettgen, MD, Associate Professor of Medicine, Harvard Medical School, Director of Preventive Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Financial Disclosure and Conflicts of Interest

David Wolinsky MD, FACC, MASNC: Consultant – Astellas Pharma; Speakers’ Bureau – Astellas Pharma; Chair Health Policy Committee – American Society Nuclear Cardiology; Chair Refer Wisely Task Force – American Society Nuclear Cardiology; Speakers Bureau – Akcea, Alnylam

Ms. Seaman: Advisory Board—Mölnlycke

Dr. Oettgen has disclosed no relevant financial relationships with any commercial interests. 

Ms. Browne, Ms. Duda, Ms. Johnson, Ms. Ilcyn, Mr. Kunkler, and Ms. Steinmayr, NACCME, have disclosed no relevant financial relationships with any commercial interests.

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service. All other NACCME planning staff have no financial relationships to disclose.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by an educational grant from Astellas.